Bevitine is named as an intervention in 2 current clinical trials in our China and France registers. 1 is recruiting patients now. The most common phase is Not applicable. The sponsor with the most trials is Shanghai Zhongshan Hospital (1). The most-studied condition is Familial Adenomatous Polyposis (FAP).
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Efficacy of Early Intravenous High-dose Vitamin C in Post-cardiac Arrest Shock.
NCT05817851 · ClinicalTrials.gov ↗ · Cardiac Arrest
|
Phase 2 | Recruiting | Centre Hospitalier de Bethune | France |
|
Efficacy of Vitamin B1 in Familial Adenomatous Polyposis Patients.
NCT06649825 · ClinicalTrials.gov ↗ · Familial Adenomatous Polyposis (FAP)
|
Not applicable | By invitation | Shanghai Zhongshan Hospital | China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| Shanghai Zhongshan Hospital | 1 |
| Centre Hospitalier de Bethune | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 1 | 0 |
| Clinical trials in France | 1 | 1 |
A trial with sites in more than one country appears in each of those registers.
2 current trials in our China and France registers name Bevitine (also registered as Vitamin B1) as a drug or biological intervention, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.
Yes. 1 of the 2 trials is recruiting: 1 with sites in France. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Shanghai Zhongshan Hospital (1) and Centre Hospitalier de Bethune (1). The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Bevitine works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Bevitine works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Bevitine (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 26 Sep 2026.